[
  {
    "ts": "2026-02-02T12:05:00+00:00",
    "headline": "Edwards Lifesciences to Present at the TD Cowen 46th Annual Health Care Conference",
    "summary": "IRVINE, Calif., February 02, 2026--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 46th Annual Health Care Conference on Monday, Mar. 2, 2026.",
    "url": "https://finance.yahoo.com/news/edwards-lifesciences-present-td-cowen-120500279.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "a393ffdc-f4d7-3ee8-846a-148d4768600c",
      "content": {
        "id": "a393ffdc-f4d7-3ee8-846a-148d4768600c",
        "contentType": "STORY",
        "title": "Edwards Lifesciences to Present at the TD Cowen 46th Annual Health Care Conference",
        "description": "",
        "summary": "IRVINE, Calif., February 02, 2026--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 46th Annual Health Care Conference on Monday, Mar. 2, 2026.",
        "pubDate": "2026-02-02T12:05:00Z",
        "displayTime": "2026-02-02T12:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/963755d83cc964f58f4dcddcdde9fa1b",
          "originalWidth": 392,
          "originalHeight": 480,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dzibzWGFH3h1Kgx2C2c.7g--~B/aD00ODA7dz0zOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/963755d83cc964f58f4dcddcdde9fa1b.cf.webp",
              "width": 392,
              "height": 480,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ev3gAP4xBDVZCylrx0.oDw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/963755d83cc964f58f4dcddcdde9fa1b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-present-td-cowen-120500279.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-present-td-cowen-120500279.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            },
            {
              "symbol": "META"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T14:10:42+00:00",
    "headline": "Edwards Lifesciences Refocuses On Core TAVR And Mitral Growth Story",
    "summary": "Edwards Lifesciences (NYSE:EW) is ending its planned acquisition of JenaValve. The company is redirecting the capital that would have gone to the deal into its internal transcatheter aortic valve replacement (TAVR) and mitral valve programs. This move reflects a shift toward developing in house platforms instead of expanding through this external transaction. Edwards Lifesciences is a major player in structural heart therapies, with TAVR and mitral valve technologies at the center of its...",
    "url": "https://finance.yahoo.com/news/edwards-lifesciences-refocuses-core-tavr-141042246.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "f9b32e52-ecbf-3eba-b2cd-51046c51b57b",
      "content": {
        "id": "f9b32e52-ecbf-3eba-b2cd-51046c51b57b",
        "contentType": "STORY",
        "title": "Edwards Lifesciences Refocuses On Core TAVR And Mitral Growth Story",
        "description": "",
        "summary": "Edwards Lifesciences (NYSE:EW) is ending its planned acquisition of JenaValve. The company is redirecting the capital that would have gone to the deal into its internal transcatheter aortic valve replacement (TAVR) and mitral valve programs. This move reflects a shift toward developing in house platforms instead of expanding through this external transaction. Edwards Lifesciences is a major player in structural heart therapies, with TAVR and mitral valve technologies at the center of its...",
        "pubDate": "2026-02-02T14:10:42Z",
        "displayTime": "2026-02-02T14:10:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9u7koo0rZkPGzBeI1l4rsQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5J1KBMD97NZX1sIZ71qfPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-refocuses-core-tavr-141042246.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-refocuses-core-tavr-141042246.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T14:09:27+00:00",
    "headline": "Should Weakness in Edwards Lifesciences Corporation's (NYSE:EW) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?",
    "summary": "It is hard to get excited after looking at Edwards Lifesciences' (NYSE:EW) recent performance, when its stock has...",
    "url": "https://finance.yahoo.com/news/weakness-edwards-lifesciences-corporations-nyse-140927690.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "55ebd17c-e2f6-3a38-af13-c5c8ea72884d",
      "content": {
        "id": "55ebd17c-e2f6-3a38-af13-c5c8ea72884d",
        "contentType": "STORY",
        "title": "Should Weakness in Edwards Lifesciences Corporation's (NYSE:EW) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?",
        "description": "",
        "summary": "It is hard to get excited after looking at Edwards Lifesciences' (NYSE:EW) recent performance, when its stock has...",
        "pubDate": "2026-02-02T14:09:27Z",
        "displayTime": "2026-02-02T14:09:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9u7koo0rZkPGzBeI1l4rsQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5J1KBMD97NZX1sIZ71qfPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/weakness-edwards-lifesciences-corporations-nyse-140927690.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/weakness-edwards-lifesciences-corporations-nyse-140927690.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]